Working through two subsidiaries, life sciences giant Bayer is taking multiple shots at Parkinson’s disease. In addition to Bayer’s efforts to tackle Parkinson’s, Adhera Therapeutics announced that the company will acquire a new class of drug aimed at the disease.
With $29 million in the company’s pocket, biotech Libra Therapeutics launched to take on neurodegenerative disease, with three pre-clinical programs ready to roll.
Boston-based resTORbio announced topline data from the PROTECTOR 1 Phase III trial of RTB101 in clinically symptomatic respiratory illness (CSRI) in adults age 65 and older.
Merck & Co. plunked down $576 million to acquire San Diego-based Calporta Therapeutics Inc. to gain access to preclinical TRPML1 agonists that are seen as potential treatments for neurodegenerative disorders such as Alzheimer’s and Parkinson’s.
Shares of Israel-based Intec Pharma Ltd. were down nearly 82 percent after the company announced that the Phase III Parkinson’s disease therapy Accordion Pill failed to demonstrate statistical superiority to treatment with Sinemet, a combination of carbidopa and levodopa.
Centogene announced the initiation of a 24-month global study to investigate the genetic factors in Parkinson’s disease.
Japanese scientists said they will start clinical trials in August 2018 on a treatment for Parkinson’s disease, transplanting “reprogrammed” stem cells into brains, seeking a breakthrough in treating the neurodegenerative disorder.